VANDEFITEMCEL
UNII ABC5EQ6K2Y

Substance Identification & Data

This profile provides standardized clinical and technical data for Vandefitemcel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) ABC5EQ6K2Y.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

ABC5EQ6K2Y

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VANDEFITEMCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188551

National Cancer Institute reference terminology for clinical and research data.

INN ID

10391

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

VANDEFITEMCEL

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vandefitemcel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VANDEFITEMCEL

Common Names & Synonyms

Vandefitemcel (Human differentiation-restricted descendents (DRCs) of bone-marrow-derived adherent stromal cells (MASCs) isolated from adult donor. To obtain DRCs, MASCs were transiently transfected with a DNA plasmid encoding human Notch-1 intracellular domain (NICD) and expanded in growth media. The transduction does not result in permanent incorporation of the gene into the cells, but does result in changes in a number of proteins and in the methylation pattern of the DNA (there is complete loss of recombinant NICD protein and of the plasmid in the final cell population). The transduction changes the nature of the cells such that they no longer readily differentiate into bone, cartilage or adipose cells, and also results in cells altered in their ability to secrete trophic and chemotactic factors, and extracellular matrix proteins to support damaged neural cells. Cells are positive for mesenchymal stem cell (MSC) markers (CD29, CD90, CD105) and negative for hematopoietic markers (CD31, CD34, CD45))

vandefitemcel [INN]

External Clinical & Regulatory Resources

Previous UNIIABC20759M6

Next UNIIABC6L5D75I